MedPath
FDA Approval

Dihydroergotamine Mesylate Nasal

FDA-approved pharmaceutical product with comprehensive regulatory information, manufacturing details, and complete labeling documentation.

FDA Approval Summary

Company
Cipla USA Inc.
DUNS: 078719707
Effective Date
January 13, 2024
Labeling Type
HUMAN PRESCRIPTION DRUG LABEL
Dihydroergotamine(4 mg in 1 mL)

Registrants1

Companies and organizations registered with the FDA for this drug approval, including their contact information and regulatory details.

Cipla USA Inc.

078719707

Manufacturing Establishments1

FDA-registered manufacturing facilities and establishments involved in the production, packaging, or distribution of this drug product.

Mipharm SpA

Cipla USA Inc.

Cipla USA Inc.

514042399

Products1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

Dihydroergotamine Mesylate Nasal

Product Details

NDC Product Code
69097-503
Application Number
ANDA212907
Marketing Category
ANDA (C73584)
Route of Administration
NASAL
Effective Date
January 24, 2024
Code: 81AXN7R2QTClass: ACTIBQuantity: 4 mg in 1 mL
CAFFEINEInactive
Code: 3G6A5W338EClass: IACT
ANHYDROUS DEXTROSEInactive
Code: 5SL0G7R0OKClass: IACT
CARBON DIOXIDEInactive
Code: 142M471B3JClass: IACT
WATERInactive
Code: 059QF0KO0RClass: IACT
© Copyright 2025. All Rights Reserved by MedPath